News

Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio® in Gastrointestinal Diseases at Digestive Disease Week® (DDW) 2021 Virtual™

20 May 2021

Further validation of how the use of Cellvizio potentially impacts patient management and improves outcomes in multiple gastrointestinal indications 

Mauna Kea Technologies today announced the presentation of 7 abstracts supporting Cellvizio® at Digestive Disease Week® (DDW) 2021 Virtual™, being held May 21-23. These abstracts focus on Barrett’s esophagus (BE), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and associated food allergies, pancreatic cysts and other gastrointestinal diseases. Studies are focused on how the use of Cellvizio potentially impacts patient management and improves outcomes. 

“Real-time in vivo cellular imaging with Cellvizio is once again taking center stage at Digestive Disease Week as evidenced by the many high-quality studies presented this year,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “We are excited to see the number and range of studies being presented and discussed, supporting how the use of Cellvizio potentially impacts patient management and improves outcomes in Barrett’s esophagus, pancreatic cysts, and inflammatory bowel disease applications, and highlighting the important new role Cellvizio could play in the management of patients suffering from irritable bowel syndrome, a chronic functional disorder of the gastrointestinal system affecting approximately 9.2% of the global population1.” 

Highlighted featured presentations (in chronological order): 

CONFOCAL LASER ENDOMICROSCOPY IN THE COLONIC MUCOSA OF PATIENTS WITH DIVERTICULAR DISEASE: INTERIM RESULTS 
Presentation #156 
Friday, May 21 from 1:47 – 1:53 p.m. ET 
Presenting Author: Miguel Puga-Tejada, Instituto Ecuatoriano de Enfermedades Digestiva, Ecuador 

ACCURACY AND AGREEMENT OF AN INTERNATIONAL PANEL FOR THE DIAGNOSIS OF PANCREATIC CYSTIC LESIONS USING EUS-GUIDED NEEDLE-BASED CONFOCAL LASER ENDOMICROSCOPY 
Presentation #78 
Friday, May 21 from 2:02 – 2:16 p.m. ET 
Presenting Author: Jorge Machicado, Mayo Clinic Health System, Eau Claire, Wisconsin, United States 

CONFOCAL LASER ENDOMICROSCOPY IN COMBINATION WITH MOLECULAR BIOMARKERS FOR THE DIAGNOSIS OF INCONSPICUOUS DYSPLASIA IN BARRETT'S ESOPHAGUS: A RANDOMISED CROSS-OVER TRIAL 
Presentation #227 
Friday, May 21 from 1:47 – 1:53 p.m. ET 
Presenting Author: Mathew Vithayathil, MRC Cancer Unit, University of Cambridge, Redhill, United Kingdom 

FOOD ALLERGY SENSITIVITY TEST (FAST) WITH ENDOMICROSCOPY OF THE DUODENUM ENABLES TAILORED EXCLUSION DIET IN PATIENTS WITH IRRITABLE BOWEL SYNDROM
Presentation #819 
Sunday, May 23 from 4:08 – 4:16 p.m. ET 
Presenting Author: Ralf Kiesslich, HELIOS Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Hessen, Germany 

Featured poster sessions (in chronological order): 

RESPONSE TO BIOLOGICS IN IBD PATIENTS ASSESSED BY COMPUTERIZED IMAGE ANALYSIS OF PROBE BASED CONFOCAL LASER ENDOMICROSCOPY WITH MOLECULAR LABELING 
Poster #Fr596 
Friday, May 21 from 12:15 – 1:00 p.m. ET 
Presenting Author: Marietta Iacucci, Institute Translational of Medicine, Institute of Immunology and Immunotherapy and NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK, Birmingham, United Kingdom 

PROBE BASED CONFOCAL ENDOMICROSCOPY MAY INCREASE DETECTION OF LOW GRADE DYSPLASIA IN MALE VETERANS PREVIOUSLY DIAGNOSED WITH NON DYSPLASTIC SHORT SEGMENT BARRETT'S ESOPHAGUS UNDERGOING SURVEILLANCE 
Poster #Fr223 
Friday, May 21 from 12:15 – 1:00 p.m. ET 
Presenting Author: Karen Chang, University of California System, Oakland, California, United States 

DEVELOPMENT OF CONFOCAL ENDOMICROSCOPY CRITERIA FOR EARLY SIGNET-RING CELL CARCINOMA IN PATIENTS WITH HEREDITARY DIFFUSE GASTRIC CANCER SYNDROME 
Poster # Su585 
Sunday, May 23 from 12:15 – 1:00 p.m. ET 
Presenting Author: Nastazja Dagny Pilonis, Department of Gastroenterological Oncology, Maria-Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, Warsaw, Poland; MRC Cancer Unit, Cambridge, United Kingdom 

Visitors are invited to visit our DDW 2021 virtual page: https://www.landing.maunakeatech.com/en/ddw-2021 


1. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Erratum in: Lancet Gastroenterol Hepatol. 2020 Dec;5(12):e8. PMID: 32702295.  

Latest News

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024